Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial

Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is associated with frequent toxicities leading to dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Dotinga, Maaike, Vriens, Dennis, van Velden, Floris H. P., Stam, Mette K., Heemskerk, Jan W. T., Dibbets-Schneider, Petra, Pool, Martin, Rietbergen, Daphne D. D., de Geus-Oei, Lioe-Fee, Kapiteijn, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777156/
https://www.ncbi.nlm.nih.gov/pubmed/36553163
http://dx.doi.org/10.3390/diagnostics12123154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777156/
https://www.ncbi.nlm.nih.gov/pubmed/36553163
http://dx.doi.org/10.3390/diagnostics12123154

Ejemplares similares